A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies

ABSTRACT Background Temsirolimus is an mTOR antagonist with proven anticancer efficacy. Preclinical data suggest greater anticancer effect when mTOR inhibitors are combined with cytotoxic chemotherapy. We performed a Phase I assessment of the combination of temsirolimus and capecitabine in patients...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Neel D. Trivedi, Samantha Armstrong, Hongkun Wang, Marion Hartley, John Deeken, A. Ruth He, Deepa Subramaniam, Heather Melville, Chris Albanese, John L. Marshall, Jimmy Hwang, Michael J. Pishvaian
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2021-03-01
coleção:	Cancer Medicine
Assuntos:	5‐fluorouracil capecitabine colorectal cancer mTOR temsirolimus
Acesso em linha:	https://doi.org/10.1002/cam4.3672
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!